Evaluation of the FIM - a Non Invasive Device for Temporarily and Quick Pupil Dilation (Mydriasis)

NCT ID: NCT01946828

Last Updated: 2013-09-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-31

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this clinical trial is to evaluate the FIM optimal configuration and confirm the safety and performance/efficacy of the FIM when exposed to a larger and more varied population of users.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

70 Eligible subjects will be enrolled to the study and examined with the FIM to determine the degree of pupil dilation/Contraction resistance.

The study will be conducted in two main stages: 1) pupil dilation measuring and 2) functional examination. The tests' sequence will be randomized, at least 30 minutes between each test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pupil Dilation

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Field Induced Mydriasis FIM ATI

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FIM

safety and efficacy of the FIM when exposed to a large and varied population of patients and users and operated according to its instructions for use

Group Type EXPERIMENTAL

FIM

Intervention Type DEVICE

Field Induced Mydriasis device

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FIM

Field Induced Mydriasis device

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy and not diagnosed with any chronic disease that might influence the eye and pupilary muscle.
* Age 18-45 years old.
* Willing and able to sign the informed consent, after reading the study information form

Exclusion Criteria

* Any known or diagnosed neurological disorders.
* A known medical history of ophthalmic surgery or any other disease that might influence the iris control muscle.
* Volunteers with a narrow or closed angle of the anterior chamber
* Presence of a corneal pathology which precludes measurement of the pupil dilatation
* Using of psychiatric medications
* Pregnancy
* Recent use (last 48hr) of pupil dilator eye drops.
* The volunteer is participating in other trials using drugs or devices
* Drug or alcohol abuse
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tel-Aviv Sourasky Medical Center

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tel-Aviv Sourasky Medical Center

Tel Aviv, , Israel

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Israel

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Keren El Ogalbo

Role: CONTACT

Phone: 972-36974165

Email: [email protected]

Adi Gluzberg

Role: CONTACT

Phone: +972-52-6401020

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Keren Elia Ogalbo

Role: primary

Adi Gluzberg

Role: backup

Related Links

Access external resources that provide additional context or updates about the study.

http://www.ati-amt.com

ATI Advanced Medical Technologies

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TASMC-13-AM-0280-CTIL

Identifier Type: -

Identifier Source: org_study_id